For this semaglutide long-term & maintenance guide, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
A patient I work with, a 52-year-old high school principal named Sandra, hit her goal weight seven months into semaglutide therapy and immediately asked the question that almost nobody talks about during the hype phase: “So now what? Do I just keep injecting forever?” It’s the single most important question in GLP-1 treatment, and the honest answer is less tidy than anyone wants it to be.
The boring truth is that maintenance on semaglutide is its own clinical phase, with its own set of trade-offs around dose, duration, cost, and the very real possibility of weight regain after stopping. The STEP-4 trial showed us that discontinuation leads to significant regain in many patients. The STEP-5 dataset gives us two years of continuous therapy data with consistent safety. What it doesn’t give us is a clean exit ramp.
What “Maintenance” Actually Means (and Doesn’t)
Once you’ve reached your target, whether that’s a number on the scale, an A1c threshold, or a set of metabolic markers your clinician cares about, you enter a phase the literature calls maintenance. It sounds stable. It often isn’t.
The core tension: the same drug that got you to your goal appears to be the thing keeping you there. STEP-4 randomized patients who had already lost weight during a 20-week semaglutide lead-in, then switched half of them to placebo. The placebo group regained substantially. The group that stayed on 2.4 mg weekly held their losses. That result is about as clear as obesity medicine gets, and it carries an uncomfortable implication.
Some patients do fine stepping down to 1.7 mg or 1.0 mg once weight stabilizes. Others can’t. The lower maintenance doses haven’t been studied with the same rigor as the full 2.4 mg, so the decision is a clinical negotiation between you and your prescriber, not something you pull from a chart.
How the Drug Works (Brief, Because You Probably Already Know)
Semaglutide is a GLP-1 receptor agonist dosed once weekly by subcutaneous injection. GLP-1 is an incretin hormone your gut releases after eating. The receptors sit in the pancreas, the GI tract, and critically, in brain regions that regulate hunger.
The practical effects: glucose-dependent insulin release, suppressed glucagon after meals, slower gastric emptying, and reduced appetite via hypothalamic signaling. That combination produced the weight and metabolic results that made the STEP program famous.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in placebo (Wilding et al., New England Journal of Medicine, 2021). STEP-3 layered intensive behavioral therapy on top and pushed results slightly higher. STEP-5 extended follow-up to 104 weeks and showed sustained reduction in the active arm. The SUSTAIN program established cardiovascular and glycemic benefits at diabetes-range doses (0.5 mg, 1.0 mg, later 2.0 mg in SUSTAIN FORTE), and SUSTAIN-6 (Marso et al.) showed reduced major adverse cardiovascular events in high-risk diabetes patients.
All of which is to say: the drug works. The question for maintenance patients isn’t whether it works. It’s what happens when you try to stop.
The Titration Schedule and Why It Matters During Maintenance
The standard escalation mirrors the Wegovy label: 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each step held four weeks. Full ramp takes about sixteen to seventeen weeks.
Compounded programs typically follow the same milligram increments, though concentrations and injection volumes vary by pharmacy. (If you’re switching between programs, confirm the milligram dose at each step. Volume means nothing without knowing the concentration.)
The schedule can flex. A patient struggling with nausea at 0.5 mg can camp there for an extra four weeks. A patient who’s clinically stable and satisfied at 1.7 mg can stay put rather than pushing to 2.4 mg. This is medicine, not a checklist.
In maintenance, the options become: hold at 2.4 mg indefinitely, step down to 1.7 mg or 1.0 mg once weight is stable, or attempt a taper toward discontinuation. There is no published standardized taper protocol. Some clinicians stretch the dosing interval (every ten days, then every two weeks). Some drop the milligrams stepwise. Some stop cold. The approach that works is the one you and your clinician agree on with eyes open about the STEP-4 data.
See also: Online Dispute Resolution Systems
Side Effects: What Changes (and What Doesn’t) Over Time
GI side effects dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These were the headline complaints across both the STEP and SUSTAIN programs and they show up reliably in real-world cohorts too. Most are mild to moderate and concentrated in the first eight to twelve weeks. By maintenance, many patients find their GI symptoms have faded or become manageable.
Less common but worth knowing about: gallbladder events (higher risk with rapid weight loss, think of it like the gallstone risk after bariatric surgery), acute pancreatitis (rare, but severe abdominal pain radiating to the back demands immediate evaluation), and a theoretical thyroid C-cell tumor signal from rodent studies that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning on the thyroid finding and contraindicate use in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Hypoglycemia is uncommon in non-diabetic patients on semaglutide alone because insulin release is glucose-dependent. Combine it with insulin or sulfonylureas in diabetes management, though, and hypo risk rises. Dose adjustment of those concurrent agents is the relevant intervention.
Long-term safety data at 2.4 mg now extends past two years via STEP-5, with a consistent signal. Cardiovascular safety in diabetes patients rests on SUSTAIN-6. For compounded preparations specifically, long-term safety data is thinner and depends partly on the manufacturing quality of the source pharmacy. That’s a real difference, not a scare tactic.
Cost, Access, and the Compounding Question
Brand-name Wegovy and Ozempic list above $1,300 per month. Cash-pay at most retail pharmacies lands somewhere between $1,000 and $1,400. Insurance coverage for weight management indications remains spotty. Diabetes indications do better but vary widely by plan.
Compounded semaglutide programs operating through compliant telehealth structures price significantly lower. HealthRX, for instance, runs $179.99 to $279.99 per month depending on dose, available in 44 states and operated under LegitScript certification.
The price gap is real and it’s structural. Brand products carry the full cost burden of Phase III trials, FDA submissions, post-marketing surveillance, and the margin Novo Nordisk needs to fund GLP-1 molecules still in the pipeline. Compounded preparations come through a different regulatory pathway, produced by state-licensed or 503A compounding pharmacies, with a fundamentally different cost structure.
The comparison between compounded and brand-name semaglutide is best understood as two supply pathways for the same active ingredient. The brand product has registrational trial data behind it, an FDA-approved label, and industrial-scale manufacturing by Novo Nordisk. The compounded preparation contains the same molecule, is prepared for individual patients, and is not FDA-approved as a finished product. The clinical evidence from STEP and SUSTAIN was built on the brand product. It informs our understanding of compounded semaglutide but doesn’t directly extend to it. Manufacturing oversight differs. Adverse-event surveillance is less complete for compounded versions.
None of that means compounded semaglutide is inherently unsafe. It means the frameworks are different, and a good program names those differences during intake rather than burying them.
If you’re using HSA or FSA funds, confirm the program’s invoicing format before enrolling. Some plans accept it, some don’t, and it depends on documentation.
The Maintenance Conversation That Matters Most
Sandra, the principal I mentioned, ended up staying at 1.7 mg. She tolerates it well, her metabolic numbers held, and she made a deliberate choice to accept a slightly higher dose in exchange for the appetite regulation she considers non-negotiable given her schedule. That’s a reasonable call. So is the call another patient made to try stepping down to 1.0 mg and seeing what held. So is the decision to attempt discontinuation after two years with a slow taper and a plan to restart if regain crosses a threshold.
What isn’t reasonable is making any of those decisions without understanding the STEP-4 data, without a clinician monitoring your trajectory, and without a plan for what to do if things slide.
Patients who want a thorough reference for the maintenance phase, including dosing frameworks, discontinuation strategies, and what the trial data actually shows about long-term use, can read this semaglutide long-term & maintenance guide. It’s structured around the clinical and practical questions that come up in a real intake conversation. It doesn’t replace that conversation, but it makes it considerably more productive.
When to Contact Your Clinician Immediately
Persistent severe abdominal pain, especially with radiation to the back or fever. Inability to keep fluids down for more than 24 hours. Signs of dehydration or persistent vomiting. New gallbladder symptoms (right upper quadrant pain after meals, jaundice). New or worsening reflux that doesn’t respond to meal-timing adjustments. Mood changes, including new or worsening depression. Pregnancy, planned pregnancy, or breastfeeding (talk to your prescriber before your next dose). Personal or family history of medullary thyroid carcinoma or MEN2 that wasn’t surfaced at intake (have that conversation now). Hypoglycemic episodes if you’re on insulin, sulfonylureas, or other glucose-lowering agents. And if you’re on warfarin or other narrow-therapeutic-window drugs, discuss whether slowed gastric emptying might be affecting absorption.
Frequently Asked Questions
How long do I stay on therapy? Individualized. STEP-5 supports two years of continuous therapy with consistent safety. Many patients continue beyond that under clinician direction. There is no predetermined stop date baked into the protocol.
Can I step down to a lower dose? Some patients hold at 1.7 mg or 1.0 mg during maintenance. These lower doses haven’t been formally studied the way 2.4 mg has, so the decision is clinical and individualized.
What happens if I stop? STEP-4 showed significant weight regain in the group switched to placebo after a lead-in period. Real-world experience tracks that finding. How much regain occurs depends partly on the lifestyle patterns consolidated during therapy.
Is there a tapering protocol? No standardized taper exists. Some clinicians extend the dosing interval, some reduce dose stepwise, some discontinue directly. The right approach is negotiated with your prescriber.
Will my appetite come back? Many patients report appetite returning toward baseline within weeks of stopping. The behavioral habits built during treatment are the variable that determines what happens after that.
Is compounded semaglutide the same as Wegovy? Same active ingredient, different supply pathway. Brand Wegovy is FDA-approved and manufactured by Novo Nordisk. Compounded semaglutide is prepared by licensed compounding pharmacies and is not FDA-approved as a finished product.
Does insurance cover maintenance dosing? Coverage for weight-management indications remains inconsistent. Some plans cover it, many don’t. Diabetes indications typically have better coverage but still vary by plan.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
